Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Spot reduction

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    54 result(s) found for: Spot reduction. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2004-000356-17 Sponsor Protocol Number: 2 79 58035 700 Start Date*: Information not available in EudraCT
    Sponsor Name:Beaufour Ipsen Pharma
    Full Title: PHASE IIIB, INTERNATIONAL, SINGLE GROUP, OPEN STUDY TO DEFINE AN OPTIMAL MONITORING OF IGF-I IN CHILDREN TREATED WITH NUTROPINAQ USING A NOVEL CAPILLARY BLOOD COLLECTION METHOD
    Medical condition: growth failure associated with: - inadequate growth hormone secretion - Turner syndrome, confirmed by karyotype - chronic renal insufficiency up to renal transplantation
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Completed) DK (Completed) AT (Completed) SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2013-000893-32 Sponsor Protocol Number: 008171BLT Start Date*: 2014-02-17
    Sponsor Name:Queen Mary University of London
    Full Title: Squamous cell carcinoma prevention in organ transplant recipients using topical treatments: a feasibility study (SPOT)
    Medical condition: Actinic keratosis (and cutaneous squamous cell carcinoma)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002038-35 Sponsor Protocol Number: S62619 Start Date*: 2019-06-27
    Sponsor Name:UZ Leuven
    Full Title: A prospective study investigating ustekinumab concentrations through dried blood spot sampling in Crohn’s disease patients
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002024-24 Sponsor Protocol Number: AUH-2016-100 Start Date*: 2017-09-08
    Sponsor Name:Aarhus Unversity Hospital
    Full Title: Randomized, cohort study of standardized reduction of subcutaneous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy
    Medical condition: Chronic inflammatory demyelinating polyneuroapthy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000014567 10077384 Chronic inflammatory demyelinating polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-000331-16 Sponsor Protocol Number: C-935788-050 Start Date*: 2014-07-28
    Sponsor Name:Rigel Pharmaceuticals Inc
    Full Title: A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy
    Medical condition: IgA nephropathy (IgAN)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000895-16 Sponsor Protocol Number: SPP100C2201 Start Date*: 2005-04-01
    Sponsor Name:Novartis Ireland Ltd
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of aliskiren on proteinuria when added to standardized losartan therapy and optimal antihyp...
    Medical condition: patients with hypertension, Type 2 DM and proteinuria
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) SK (Prematurely Ended) DK (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003826-10 Sponsor Protocol Number: EAGLE Start Date*: 2014-01-24
    Sponsor Name:IRCCS- Mario Negri Institute
    Full Title: EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA
    Medical condition: Membranoproliferative glomerulonephritis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018313-29 Sponsor Protocol Number: PPA/904A/001 Start Date*: 2010-03-23
    Sponsor Name:Photopharmica
    Full Title: Open-label, within-subject controlled, Phase IIa study to investigate repeat dose antimicrobial photodynamic therapy in patients with acne vulgaris.
    Medical condition: Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    12.1 10000519 Acne Vulgaris LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005835-60 Sponsor Protocol Number: APHP200038 Start Date*: 2021-08-11
    Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP)
    Full Title: Induction therapy for lupus nephritis with no added oral corticosteroids : An open label randomised multicentre controlled trial comparing oral corticosteroids plus mycophenolate mofetil (MMF) ve...
    Medical condition: The study population will consist of Children (14 years and above) and adults (until 75 years old) with lupus nephritis ISN/RPS class III or IV (A or A/C) ± V with active lesions in at least 10% of...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002716-27 Sponsor Protocol Number: ALN-CC5-005 Start Date*: 2019-06-11
    Sponsor Name:Alnylam Pharmaceuticals Inc
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients with IgA Nephropathy
    Medical condition: Immunoglobulin A nephropathy (IgAN)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004815-33 Sponsor Protocol Number: TransCon_PTH_TCP-201 Start Date*: 2019-09-27
    Sponsor Name:Ascendis Pharma Bone Diseases A/S
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial with an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administ...
    Medical condition: Hypoparathyroidism (HP) in Adults
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10021041 Hypoparathyroidism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2019-003265-17 Sponsor Protocol Number: S63466 Start Date*: 2020-09-10
    Sponsor Name:Universitair Ziekenhuis Leuven (UZ Leuven)
    Full Title: Phase II, dose ranging, efficacy study of anti-thymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes (T1D)
    Medical condition: Type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FI (Completed) SI (Completed) AT (Completed) IT (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003089-96 Sponsor Protocol Number: 204851 Start Date*: 2016-01-06
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multi-centre Phase IIa double-blind, placebo-controlled study to investigate the efficacy and safety of GSK3196165 in subjects with inflammatory hand osteoarthritis.
    Medical condition: Inflammatory Hand Osteoarthritis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004859 10019115 Hand osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-005710-19 Sponsor Protocol Number: M13-958 Start Date*: 2013-10-28
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High ...
    Medical condition: Acute Kidney Injury
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10069339 Acute kidney injury LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004893-25 Sponsor Protocol Number: CRO2035 Start Date*: 2014-07-08
    Sponsor Name:Imperial College London
    Full Title: RITUXILUP - An open label randomised multicentre controlled trial of RITUXImab and mycophenolate mofetil (MMF) without oral steroids for the treatment of LUPus nephritis
    Medical condition: Lupus nephritis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001331-48 Sponsor Protocol Number: D9481C00001 Start Date*: 2019-03-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3, Dose-Escalating Study in Children With Hyperkalaemia Between Birth and <18 Years of Age to Evaluate Increasing Doses of Sodium Zirconium Cyclosilicate (SZC) Given Three Times Daily for t...
    Medical condition: Hyperkalaemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10020647 Hyperkalemia LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Trial now transitioned) RO (Trial now transitioned) DE (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002750-31 Sponsor Protocol Number: LAL-CL02 Start Date*: 2013-05-29
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A multicenter, randomized, placebo-controlled study of SBC-102 in patients with lysosomal acid lipase deficiency
    Medical condition: Lysosomal Acid Lipase Deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004915 10024579 Lysosomal storage disorders HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed) ES (Completed) CZ (Completed) PL (Completed) GR (Completed) HR (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-005951-14 Sponsor Protocol Number: AIFA ESRD Start Date*: 2007-01-25
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: A prospective, randomized, open label blinded end point probe trial to evaluate whether, at comparable blood pressure control, combined therapy with the ACE inhibitor Benazepril and the angiotens...
    Medical condition: Diabetic nephropathy
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061835 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2011-005696-17 Sponsor Protocol Number: 1645-CI-058 Start Date*: 2013-06-18
    Sponsor Name:Instituto de Investigacion Sanitaria La Fe
    Full Title: Multicenter, randomized, blinded clinical study comparing early use of total body moderate hypothermia plus topiramate or placebo in asphyxiated newborn infants evolving to moderate-to-severe hypox...
    Medical condition: Asphyxiated newborn infants evolving to moderate-to-severe hypoxic ischemic encephalopathy
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002862-42 Sponsor Protocol Number: D3466C00001 Start Date*: 2022-02-11
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis
    Medical condition: Active Proliferative Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 17:46:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA